PTC Therapeutics Inc. has released its financial outlook for 2026, projecting total product revenue in the range of $700 to $800 million, which represents a year-over-year growth of 19% to 36%. The company reported unaudited 2025 total product and royalty revenue of approximately $823 million, exceeding its previous guidance. In 2025, product revenue reached around $587.8 million, with Sephience netting approximately $112.1 million since launch. For 2026, PTC anticipates GAAP research and development (R&D) and selling, general, and administrative (SG&A) expenses to be between $775 million and $815 million. On a non-GAAP basis, excluding estimated non-cash, stock-based compensation expense, R&D and SG&A expenses are expected to be $680 million to $720 million. The company also reported a strong cash position of about $1.94 billion as of December 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY60762) on January 12, 2026, and is solely responsible for the information contained therein.